ARCA biopharma, Inc.

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). Show More...

  • Website http://www.arcabio.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 2.40 USD
  • Last Updated 30-08-2024
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -748.43 -404.46 -244.44 -131.04 -59.58 -32.76 -32.58 -31.86 -10.31 -4.15 -3.12
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 1.0 1.0 1.0
    Book Value Per Share * USD 579.46 360.66 137.69 147.56 102.45 81.72 52.48 21.94 9.65 5.52 3.96
    Free Cash Flow Per Share * USD -740.2 -542.49 -231.09 -96.63 -62.01 -37.01 -27.35 -31.59 -15.01 -4.47
    Return on Assets % -96.07 -73.19 -88.94 -88.34 -58.34 -41.09 -51.28 -99.87 -82.66 -71.38 -63.96
    Financial Leverage (Average) 1.2 1.13 1.1 1.1 1.09 1.04 1.11 1.2 1.13 1.12 1.18
    Return on Equity % -118.73 -85.8 -100.01 -96.98 -63.91 -43.34 -54.64 -113.79 -97.27 -80.37 -75.43
    Return on Invested Capital % -129.38 -85.76 -99.99 -96.99 -63.93 -43.38 -55.2 -114.78 -99.15 -82.72 -77.59
    Interest Coverage -994.5 -806.0 -651.88
    Current Ratio 6.02 8.24 9.98 11.27 11.16 25.88 8.95 5.94 8.54 9.16 6.39
    Quick Ratio 5.9 7.88 9.57 11.16 11.06 25.8 8.83 5.68 8.33 9.03 5.78
    Debt/Equity